retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 is a triple-agonist drug targeting GLP-1, GIP, and receptors to suppress appetite and boost thermogenesis. trials reported 24.2% average weight loss and over 80% liver fat reduction, reversing Retatrutide for Obesity: Phase 2
Description
Accordingly, integration of structured nutritional surveillance with pharmacological therapy may represent an important component of long-term GLP-1RA management

86 Finally, patients taking GLP-1RAs reduce caloric intake by 16%-39%, with some reporting 35%-40% reduction in high-fat food, 12.2% reduction in carbohydrate intake, and significant decreases in cravings for salty, spicy, dairy, and starchy foods

"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults" (PDF)

the first is when a rapid pharmacological effect is required, such as with anti-hyperglycemic drugs that affect immediate post-prandial glucose excursions [48, 54]

Epub 2024 Feb 27

We present hypotheses centered on the mechanisms of GLP-1 RAs, proposing them as potential modulators of aging hallmarks and longevity
